Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SSY Group ( (HK:2005) ) just unveiled an update.
SSY Group Limited has secured approval from China’s National Medical Products Administration for its Azilsartan Medoxomil Potassium to be used as a bulk drug in preparations already on the market. The product targets primary hypertension in adults, and the approval broadens the group’s cardiovascular portfolio while potentially strengthening its competitive position in the domestic pharmaceutical supply chain and supporting future revenue growth.
The company framed the move as part of its ongoing business development, signaling to shareholders and potential investors that its pipeline is progressing and aligning with national healthcare needs. The update underscores SSY Group’s efforts to expand its offering of active pharmaceutical ingredients, which may enhance its role as a key supplier to downstream drug manufacturers amid rising demand for chronic disease treatments in China.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a pharmaceutical company focused on developing and manufacturing drug products for the Chinese healthcare market. The group operates through subsidiaries and targets therapeutic areas with significant demand, supplying bulk drugs and finished preparations to medical institutions and other industry players.
Average Trading Volume: 9,681,465
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.85B
For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.